Can NPP Cause Erectile Dysfunction? (TRT Q&As)
Timeline
A 47-year-old man who recently progressed from TRT to higher-dose testosterone, NPP, and Primobolan reports very high libido but poor erectile function. Dr. O’Connor discusses the possible role of NPP, estrogen balance, the other androgens being used, and the difficulty of identifying one cause when multiple compounds and doses are being changed.
A 59-year-old man on testosterone reports that SHBG increased from around 20 to nearly 40 while free testosterone fell substantially. Dr. O’Connor recommends repeating the testing under consistent conditions and focusing more on symptoms and free testosterone at the nadir than on trying to manipulate SHBG itself.
A 43-year-old man taking oral testosterone twice daily reports increased free testosterone but no noticeable improvement in energy, muscle retention, or overall well-being. Dr. O’Connor discusses trying an appropriately adjusted oral dose before abandoning it, while explaining that injectable testosterone may ultimately provide a more noticeable and sustainable response.
Dr. O’Connor explains that testosterone can be administered subcutaneously and says the difference is not substantial enough to require intramuscular injections for every man. He emphasizes choosing a practical, sustainable injection approach while monitoring the individual response.
The member asks whether combining HCG with his oral testosterone might improve his results. Dr. O’Connor does not recommend adding HCG without a specific need and emphasizes keeping the regimen simple and sustainable rather than continually adding medications.
A member taking 150 mg per week in two subcutaneous injections asks whether his dose is too high after a trough testosterone result around 1,200. Dr. O’Connor says one result should not determine the dose by itself and recommends considering repeat testing, symptoms, the ABCDs™, and overall health while using the lowest effective dose.
Video Summary
The discussion focuses on refining testosterone therapy once an initial response has been established. It emphasizes reassessing symptoms over time and avoiding unnecessary dose changes driven by short-term variability. Testosterone therapy is framed as a process requiring patience and consistency.
A central segment examines laboratory trends, explaining why gradual shifts provide more useful guidance than isolated results. The episode cautions against overinterpreting minor deviations and reinforces trend-based decision-making. Contextual interpretation is emphasized throughout.
The closing portion integrates testosterone therapy into long-term clinical planning. Ongoing reassessment, risk awareness, and individualized adjustment are highlighted as therapy evolves. Hormone therapy is positioned as a dynamic, monitored intervention.
Drug Callouts
Condition Callouts
Key Takeaways
- Refinement of testosterone therapy should prioritize stability.
- Symptom recalibration is necessary as therapy evolves.
- Lab trends provide better guidance than isolated values.
- Chasing minor deviations can introduce unnecessary risk.
- Long-term monitoring supports durable hormone management.